Latest Regulatory Approvals News

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

NH3 Clean Energy’s WAH2 Clean Ammonia Project has been granted Federal Major Project Status, accelerating government approvals and supporting a Final Investment Decision by end 2026.

Regis Resources Ltd (ASX:RRL) and Vault Minerals Ltd (ASX:VAU) have agreed to merge via a scheme of arrangement, forming a new senior gold producer with over 700,000 ounces annual production and a market cap near A$10.7 billion.

PMET Resources has cleared a major regulatory hurdle with federal acceptance of its Environmental and Social Impact Assessment for the Shaakichiuwaanaan lithium-tantalum-caesium project, while pushing forward updated feasibility studies and a critical power application.

Nine Entertainment’s acquisition of QMS Media and sale of Nine Radio mark a strategic pivot, with strong Q3 digital and subscription revenue growth cushioning a cautious Q4 advertising environment.

Green Technology Metals (ASX: GT1) has initiated a fully underwritten $4 million entitlement offer to fund the next phase of its Seymour Lithium Project, alongside a $7 million placement subject to shareholder approval.

Pinnacle Investment Management is boosting its stake in Metrics Credit Holdings back to 35%, investing around A$100.5 million. Simultaneously, Korea’s National Pension Service, via Townsend, is increasing its holding to nearly 10%, pending regulatory approval.

Ardea Resources’ Kalgoorlie Nickel Project’s Goongarrie Hub has been named in the Australia-Japan joint statement on critical minerals cooperation, highlighting its role in securing resilient nickel-cobalt supply chains backed by government support.

Connected Minerals (ASX:CML) is set to acquire Frontier Group CRM, gaining control of an 80% interest in the Bailundo carbonatite project in Angola, boasting near-surface high-grade niobium and rare earth mineralisation. Backed by a $4.5 million capital raise, the company aims to fast-track exploration in this emerging critical minerals jurisdiction.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.